153 related articles for article (PubMed ID: 11259927)
1. Becaplermin and necrobiosis lipoidicum diabeticorum: results of a case control pilot study.
Stephens E; Robinson JA; Gottlieb PA
J Diabetes Complications; 2001; 15(1):55-6. PubMed ID: 11259927
[TBL] [Abstract][Full Text] [Related]
2. Long-term successful healing of ulcerated necrobiosis lipoidica after topical therapy with becaplermin.
Tauveron V; Rosen A; Khashoggi M; Abdallah-Lotf M; Machet L
Clin Exp Dermatol; 2013 Oct; 38(7):745-7. PubMed ID: 23962308
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with infliximab: report of a case.
Hu SW; Bevona C; Winterfield L; Qureshi AA; Li VW
Arch Dermatol; 2009 Apr; 145(4):437-9. PubMed ID: 19380665
[TBL] [Abstract][Full Text] [Related]
5. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
Ladin D
Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNFα treatment for recalcitrant ulcerative necrobiosis lipoidica diabeticorum: A case report and review of the literature.
Basoulis D; Fragiadaki K; Tentolouris N; Sfikakis PP; Kokkinos A
Metabolism; 2016 Apr; 65(4):569-73. PubMed ID: 26975548
[TBL] [Abstract][Full Text] [Related]
8. Links between granuloma annulare, necrobiosis lipoidica diabeticorum and childhood diabetes: a matter of time?
Davison JE; Davies A; Moss C; Kirk JM; Taibjee SM; Agwu JC
Pediatr Dermatol; 2010; 27(2):178-81. PubMed ID: 20537071
[TBL] [Abstract][Full Text] [Related]
9. Atypical Ulcerative Necrobiosis Lipoidica Diabeticorum: A Case Study.
Blevins M
Int J Low Extrem Wounds; 2023 Mar; 22(1):185-189. PubMed ID: 33745343
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
[TBL] [Abstract][Full Text] [Related]
12. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
Miller MS
J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
[TBL] [Abstract][Full Text] [Related]
13. Perforating necrobiosis lipoidica in a girl with type 1 diabetes mellitus: a new case reported.
Hammami H; Youssef S; Jaber K; Dhaoui MR; Doss N
Dermatol Online J; 2008 Jul; 14(7):11. PubMed ID: 18718195
[TBL] [Abstract][Full Text] [Related]
14. Necrobiosis lipoidica diabeticorum: response to pentoxiphylline.
Basaria S; Braga-Basaria M
J Endocrinol Invest; 2003 Oct; 26(10):1037-40. PubMed ID: 14759079
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
Victor-Vega C; Desai A; Montesinos MC; Cronstein BN
Inflammation; 2002 Feb; 26(1):19-24. PubMed ID: 11936752
[TBL] [Abstract][Full Text] [Related]
16. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
Rees RS; Robson MC; Smiell JM; Perry BH
Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
[TBL] [Abstract][Full Text] [Related]
17. Two girls with necrobiosis lipoidica and type I diabetes mellitus with transfollicular elimination in one girl.
Pestoni C; Ferreirós MM; de la Torre C; Toribio J
Pediatr Dermatol; 2003; 20(3):211-4. PubMed ID: 12787268
[TBL] [Abstract][Full Text] [Related]
18. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane.
Yoon J; Giacopelli J; Granoff D; Kobayashi W
J Am Podiatr Med Assoc; 2002 Jun; 92(6):350-4. PubMed ID: 12070235
[TBL] [Abstract][Full Text] [Related]
19. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
Nagai MK; Embil JM
Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
[TBL] [Abstract][Full Text] [Related]
20. Ulcerated necrobiosis lipoidica diabeticorum in a patient with a history of generalized granuloma annulare.
Berkson MH; Bondi EE; Margolis DJ
Cutis; 1994 Feb; 53(2):85-6. PubMed ID: 7851128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
